The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma.
Orlynvah is used to treat uncomplicated urinary tract infections caused by certain microorganisms in adult women who have limited or no alternative oral antibacterial treatment options.